v3.26.1
Segment Reporting (Tables)
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of reportable segment net (loss) income

The Company's reportable segment net (loss) income for the three months ended March 31, 2026 and 2025, consisted of the following (in thousands):

 

Three Months Ended March 31,

 

 

2026

 

 

2025

 

Grant revenue

$

358

 

 

$

—

 

Significant segment expenses:

 

 

 

 

 

Live biotherapeutics platform

$

6,533

 

 

$

5,123

 

SER-155

 

647

 

 

 

577

 

R&D personnel-related (including stock-based compensation)

 

5,920

 

 

 

6,118

 

G&A personnel-related (including stock-based compensation)

 

3,291

 

 

 

4,173

 

Professional fees

 

1,714

 

 

 

3,180

 

Facility-related and other

 

3,065

 

 

 

4,535

 

Gain on sale of VOWST Business (2)

 

—

 

 

 

(52,181

)

Other segment (income) expense (1)

 

(899

)

 

 

(4,207

)

Net (loss) income

$

(19,913

)

 

$

32,682

 

[1] Other segment (income) expense includes manufacturing services expenses, research and development expenses on early stage programs, interest income and other (income) expense, net.

[2] See Note 3, Discontinued Operations and TSA, for further details.